Pharmacokinetics and dosage regimen of ceftriaxone in E. coli lipopolysaccharide induced fever in buffalo calves. 2005

Manmohan Singh Dardi, and Suresh Kumar Sharma, and Anil Kumar Srivastava
Department of Pharmacology and Toxicology, College of Veterinary Sciences, Punjab Agricultural University, Ludhiana-141004, India.

The present study was planned to investigate the pharmacokinetics of ceftriaxone in experimentally induced febrile buffalo calves (n=5). The fever was induced by intravenous injection of E.coli lipopolysaccaride (1 microgram/kg). To study the pharmacokinetics, ceftriaxone was administered at the dose rate of 10 mg/kg body wt. in all animals. At 1 min, the peak concentration of ceftriaxone was 79.4+/-2.37 microgram/ml and the drug was detected up to 6 h. The elimination rate constant was 0.35+/-0.02 /h and elimination half-life was 2.04+/-0.14 h. The apparent volume of distribution (Vd(area)) and total body clearance (Cl(B)) were 1.21+/-0.15 l/kg and 0.41+/-0.03 l/kg/h, respectively. To maintain a minimum therapeutic concentration of 1 microgram/kg, a satisfactory dosage regimen of cefriaxone in febrile buffalo calves is 19 mg/kg followed by 18 mg/kg at 8 h intervals.

UI MeSH Term Description Entries
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D002020 Buffaloes Ruminants of the family Bovidae consisting of Bubalus arnee and Syncerus caffer. This concept is differentiated from BISON, which refers to Bison bison and Bison bonasus. Bubalus,Syncerus,Water Buffaloes,Buffalo,Water Buffalo,Buffalo, Water
D002443 Ceftriaxone A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears. Benaxona,Cefatriaxone,Cefaxona,Ceftrex,Ceftriaxon,Ceftriaxon Curamed,Ceftriaxon Hexal,Ceftriaxona Andreu,Ceftriaxona LDP Torlan,Ceftriaxone Irex,Ceftriaxone Sodium,Ceftriaxone Sodium, Anhydrous,Ceftriaxone, Disodium Salt,Ceftriaxone, Disodium Salt, Hemiheptahydrate,Lendacin,Longacef,Longaceph,Ro 13-9904,Ro-13-9904,Ro13-9904,Rocefalin,Rocefin,Rocephin,Rocephine,Tacex,Terbac,Anhydrous Ceftriaxone Sodium,Ro 13 9904,Ro 139904,Ro13 9904,Ro139904
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005334 Fever An abnormal elevation of body temperature, usually as a result of a pathologic process. Pyrexia,Fevers,Pyrexias
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

Manmohan Singh Dardi, and Suresh Kumar Sharma, and Anil Kumar Srivastava
June 2006, Journal of veterinary science,
Manmohan Singh Dardi, and Suresh Kumar Sharma, and Anil Kumar Srivastava
October 1999, Veterinary research communications,
Manmohan Singh Dardi, and Suresh Kumar Sharma, and Anil Kumar Srivastava
January 1998, Acta veterinaria Hungarica,
Manmohan Singh Dardi, and Suresh Kumar Sharma, and Anil Kumar Srivastava
January 1990, Veterinary research communications,
Manmohan Singh Dardi, and Suresh Kumar Sharma, and Anil Kumar Srivastava
January 1999, Acta veterinaria Hungarica,
Manmohan Singh Dardi, and Suresh Kumar Sharma, and Anil Kumar Srivastava
January 1989, Veterinary research communications,
Manmohan Singh Dardi, and Suresh Kumar Sharma, and Anil Kumar Srivastava
January 1992, Veterinary research communications,
Manmohan Singh Dardi, and Suresh Kumar Sharma, and Anil Kumar Srivastava
January 2000, Acta veterinaria Hungarica,
Manmohan Singh Dardi, and Suresh Kumar Sharma, and Anil Kumar Srivastava
December 1999, Veterinary research communications,
Manmohan Singh Dardi, and Suresh Kumar Sharma, and Anil Kumar Srivastava
February 2008, Veterinary research communications,
Copied contents to your clipboard!